74867-91-7 Usage
Description
1-AMINO-1-DEOXY-BETA-D-GALACTOSE, also known as a galactose analogue, is a white crystalline solid with unique chemical properties. It is structurally similar to galactose, a sugar molecule, and is utilized in various applications due to its ability to act as a competitive inhibitor.
Uses
1. Used in Enzyme Research:
1-AMINO-1-DEOXY-BETA-D-GALACTOSE is used as a competitive inhibitor for [application reason] to help isolate, purify, identify, differentiate, and characterize β-D-galactosidase(s) and galactose oxidase(s). This application is particularly relevant in the field of biochemistry and molecular biology, where understanding the function and properties of enzymes is crucial.
2. Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-AMINO-1-DEOXY-BETA-D-GALACTOSE is used as a key compound for [application type] in the development of new drugs targeting enzymes related to galactose metabolism. Its ability to inhibit specific enzymes can be leveraged to create therapies for various diseases and conditions.
3. Used in Analytical Chemistry:
1-AMINO-1-DEOXY-BETA-D-GALACTOSE is used as a reference material for [application reason] in analytical chemistry, particularly in the development and validation of methods for the detection and quantification of galactose and related compounds. Its unique properties make it an ideal candidate for establishing standards and improving the accuracy of analytical techniques.
4. Used in Food Industry:
In the food industry, 1-AMINO-1-DEOXY-BETA-D-GALACTOSE is used as an additive for [application reason] to improve the taste, texture, or shelf life of certain products. Its ability to interact with other molecules may provide benefits in the development of new food products or the enhancement of existing ones.
5. Used in Material Science:
1-AMINO-1-DEOXY-BETA-D-GALACTOSE is used as a building block for [application reason] in the synthesis of novel materials with specific properties, such as improved biocompatibility or enhanced mechanical strength. Its unique chemical structure allows for the creation of innovative materials with potential applications in various industries, including medical devices and consumer products.
Check Digit Verification of cas no
The CAS Registry Mumber 74867-91-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,4,8,6 and 7 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 74867-91:
(7*7)+(6*4)+(5*8)+(4*6)+(3*7)+(2*9)+(1*1)=177
177 % 10 = 7
So 74867-91-7 is a valid CAS Registry Number.
InChI:InChI=1/C6H13NO5/c7-6-5(11)4(10)3(9)2(1-8)12-6/h2-6,8-11H,1,7H2/t2-,3+,4-,5-,6+/m1/s1
74867-91-7Relevant articles and documents
Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands
Baba, Akihito,Wakao, Masahiro,Shinchi, Hiroyuki,Chan, Michael,Hayashi, Tomoko,Yao, Shiyin,Cottam, Howard B.,Carson, Dennis A.,Suda, Yasuo
supporting information, (2019/12/27)
Toll-like receptors (TLRs) are a type of pattern recognition receptors (PRRs), which are activated by recognizing pathogen-associated molecular patterns (PAMPs). The activation of TLRs initiates innate immune responses and subsequently leads to adaptive immune responses. TLR agonists are effective immuomodulators in vaccine adjuvants for infectious diseases and cancer immunotherapy. In exploring hydrophilic small molecules of TLR7 ligands using the cell-targeted property of a vaccine adjuvant, we conjugated 1V209, a small TLR7 ligand molecule, with various low or middle molecular weight sugar molecules that work as carriers. The sugar-conjugated 1V209 derivatives showed increased water solubility and higher immunostimulatory activity in both mouse and human cells compared to unmodified 1V209. The improved immunostimulatory potency of sugar-conjugates was attenuated by an inhibitor of endocytic process, cytochalasin D, suggesting that conjugation of sugar moieties may enhance the uptake of TLR7 ligand into the endosomal compartment. Collectively our results support that sugar-conjugated TLR7 ligands are applicable to novel drugs for cancer and vaccine therapy.
Synthesis of glycosylamines: Identification and quantification of side products
Campa, Cristiana,Donati, Ivan,Vetere, Amedeo,Gamini, Amelia,Paoletti, Sergio
, p. 263 - 273 (2007/10/03)
The synthesis of some glycosylamines (1-amino-1-deoxy-D-glucose, 1-amino-1-deoxy- D-galactose and 1-amino-1-deoxylactose) was carried out by treatment of the corresponding reducing sugars with ammonium hydrogencarbonate in concentrated ammonia. The reaction mixture was first analyzed by capillary electrophoresis with indirect absorbance detection and high performance anion-exchange chromatography with pulsed amperometric detection. Beside glycosylcarbamate, a known reaction by-product, fructose and lactulose were detected during the synthesis of 1-amino-1-deoxyglucose and 1-amino-1-deoxylactose, respectively. Quantification of glycosylamines was carried out by micellar electrokinetic chromatography with UV detection of their 9-fluorenylmethyloxycarbonyl (Fmoc) derivatives; lactulosylamine was thus detected in the synthesis mixture of 1-amino-1-deoxylactose. The Fmoc-glycosylamines were easily purified from the other components of the crude synthesis mixtures.
